Drug | PNA group | No of cases | Unit dose (mg/kg/dose) | Â | Â | Dosing interval (h) | Â | ||
---|---|---|---|---|---|---|---|---|---|
 |  |  | Current study; median (quartiles) | Current study; range | BNFC/Blue book | Neofax | Current study; median (quartiles) | BNFC/the Blue book | Neofax |
Penicillin G | 0–7 days | 62 | 47 (27–53) | 10–147 | 25 (50)*# | 15–30 (45–60)* | 12 (12–12) | 12 | 12 |
N = 88 | 8–28 days | 21 | 33 (31–50) | 25–61 | 25 (50)*# | 15–30 (45–60)* | 12 (12–12) | 8 | 8–12 |
 | >28 days | 5 | 40 (30–43) | 28–43 | 25 (50)*# | 15–30 (45–60)* | 12 (10–12) | 6 (4) | 6–8 |
Ampicillin | 0–7 days | 69 | 52 (50–78) | 24–126 | 30 (60; max 62.5)* | 25–50 | 12 (12–12) | 12 | 12 |
N = 82 | 8–21 days | 6 | 52 (49–96) | 47–96 | 30 (60; max 62.5)* | 25–50 | 8 (8–12) | 8 | 8–12 |
 | 22–28 days | 4 | 47 (37–86) | 34–99 | 30 (60; max 62.5)* | 25–50 | 12 (8–12) | 6 | 8–12 |
 | >28 days | 3 | 48 (45–69) | 45–69 | 62.5 | 25–50 | 12 (8–12) | 6 | 6–8 |
Cefotaxime | 0–7 days | 16 | 46 (29–51) | 10–54 | 25 (50)* | 50 | 12 (12–12) | 12 | 12 |
N = 32 | 8–21 days | 12 | 48 (25–50) | 13–53 | 25 (50)* | 50 | 8 (8–12) | 8 | 8–12 |
 | >21 days | 4 | 47 (16–49) | 5–49 | 25 (50)* | 50 | 8 (8–8) | 6–8 | 8–12 |
Ceftazidime | 0–7 days | 6 | 30 (25–41) | 22–53 | 25 (50)*& | 30 | 12 (8–12) | 24 | 12 |
N = 20 | 8–21 days | 5 | 43 (32–47) | 27–49 | 25 (50)* | 30 | 12 (8–12) | 12 | 8–12 |
 | >21 days | 9 | 36 (30–39) | 24–47 |  | 30 | 8 (8–12) | 8 | 8–12 |
Meropenem | 0–7 days | 10 | 20 (19–22) | 9–39 | 20 (40)* | 20–40* | 12 (8–12) | 12 | 12 |
N = 20 | 8–28 days | 10 | 21 (15–30) | 9–43 | 20 (40)* | 20–40* | 10 (8–12) | 8 | 8–12 |